logo
Share SHARE
FONT-SIZE Plus   Neg

GlaxoSmithKline Receives FDA Approval For PROMACTA

GlaxoSmithKline plc (GSK) Monday said the U.S. Food and Drug Administration has approved PROMACTA for the treatment of low blood platelet counts in patients with chronic hepatitis C.

PROMACTA is the first supportive care treatment available to patients who are ineligible for interferon-based therapy due to their low blood platelet counts.

The approval for PROMACTA was based on results from ENABLE 1 and 2, a two Phase III randomized, double-blind, placebo-controlled, multicenter studies, which collectively enrolled 1,521 patients with lower platelet counts.

"Some chronic hepatitis C patients suffer from low blood platelet counts. Commonly prescribed interferon-based therapies can worsen the problem of low blood platelet counts. Today's FDA approval of PROMACTA gives doctors a tool to address the low platelet challenge, " said Paolo Paoletti, M.D., President, GlaxoSmithKline Oncology.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Seattle police caught an alleged car thief by remotely locking him inside the stolen BMW 550i with the help of the automaker. The Seattle Police Department said in its blog that the incident took place in Seattle in November. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan.
comments powered by Disqus
Follow RTT